Table 2.
Lesion and Device Characteristics of the Included Studies.
| Study | Vessel preparation device | Lesions (n) | Popliteal lesions | Calcification | Lesion length (mm) | CTO | Bailout stenting |
|---|---|---|---|---|---|---|---|
| Canaud et al 16 | CB (Boston Scientific) | 116 | 0 (0) | N/A | N/A | N/A | N/A |
| Bosiers et al 17 | CB (Angiosculpt) | 36 | 1 (3) | 17 (55) | 32.4 | N/A | 11 (36) |
| Iezzi et al 21 | CB (Boston Scientific) | 25 | 2 (8) | N/A | 17 | N/A | 0 (0) |
| Gallagher et al 22 | DA (SilverHawk) | 109 | 0 (0) | N/A | N/A | 109 (100) | N/A |
| Control (PTA) | 85 | 0 (0) | N/A | N/A | 85 (100) | ||
| Rastan et al 18 | DA (SilverHawk, TurboHawk) | 96 | 0 (0) | 30 (31) | 60 | 32 (33) | N/A |
| Shammas et al 26 | OA (Diamondback 360 OAS) | 29 | 2 (7) | 29 (100) | 91 | N/A | 2 (7) |
| Control (PTA) | 35 | 4 (11) | 35 (100) | 69 | N/A | 5 (14) | |
| Bosiers et al 19 | LA | 64 | 0 (0) | N/A | N/A | N/A | N/A |
| Control (PTA) | 79 | 0 (0) | N/A | N/A | N/A | N/A | |
| Sultan et al 20 | LA | 80 | 0 (0) | 15 (36)a | 170 | 24 (57) a | 15 (39) |
| Control (PTA) | 86 | 0 (0) | 13 (28%) a | 160 | 27 (57) a | 14 (33) | |
| Kokkinidis et al 23 | LA | 76 | 0 (0) | 25 (34) b | 165.7 | 43 (58) | 11 (14) |
| Control (PTA) | 237 | 0 (0) | 61 (27) b | 94.1 | 99 (43) | 19 (8) | |
| Todd et al 24 | DA, OA, LA (SilverHawk, Diamondback 360 OAS, Excimer) | 79 | 0 (0) | N/A | N/A | 35 (44) | 0 (0) |
| Control (PTA) | 339 | 0 (0) | N/A | N/A | N/A c (44) | 6 (2) | |
| Zia et al 25 | DA, OA (SilverHawk, Diamondback 360 OAS) | 159 | 0 (0) | N/A | 60.2 | N/A | N/A |
| Control (PTA) | 183 | 0 (0) | N/A | 65.5 | N/A | N/A | |
| Rastan et al 27 | DA (SilverHawk, TurboHark) | 40 | 0 (0) | 28 (70) b | 191.6 | 22 (55) | 6 (15) |
| Control (DCB) | 40 | 0 (0) | 30 (76.9) | 160.8 | 18 (45) | 5 (13) | |
| Zeller et al 28 | OA (Diamondback 360 OAS) | 33 | 1 (3) | 29 (100) b | 101.3 | 14 (42) | N/A |
| Control (DCB) | 37 | 0 (0) | 30 (94) b | 78.8 | 12 (32) | N/A |
Data are given as n (%) unless stated otherwise.
Abbreviations:CB, cutting balloon; CTO, chronic total occlusions; DA, directional atherectomy; DCB, drug-coated balloon; LA, laser atherectomy; OA, orbital atherectomy; PTA, percutaneous transluminal angioplasty.
a
Lesion characteristics appear to be divided by the number of procedures (Laser: 42, PTA: 47) and not the number of lesions.
b
Moderate or severe calcification.
c
In the demographics table only the exact percentage is given. However, this percentage cannot be converted into exact number of patients.